Trial
NCT03909295
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Heart Failure With Preserved Ejection Fraction (HFpEF)
Intervention
LCZ696
Why stopped
This study was terminated early because the primary endpoint of PARAGON-HF was not met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-08